|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:artemisinin-based_therapies
|
|
gptkbp:activities
|
inhibits parasite growth
|
|
gptkbp:antagonist
|
high efficacy
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
1990s
|
|
gptkbp:availability
|
widely available
|
|
gptkbp:clinical_trial
|
ongoing research
high bioavailability
|
|
gptkbp:composed_of
|
semi-synthetic process
|
|
gptkbp:defense
|
recommended for malaria treatment
|
|
gptkbp:developed_by
|
gptkb:artemisinin
Chinese scientists
|
|
gptkbp:dissolved
|
soluble in water
soluble in ethanol
|
|
gptkbp:duration
|
3 days
|
|
gptkbp:excretion
|
excreted in urine
|
|
gptkbp:formulation
|
oral suspension
injectable form
|
|
gptkbp:healthcare
|
significant impact on malaria control
|
|
gptkbp:historical_event
|
gptkb:product
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dihydroartemisinin
|
|
gptkbp:ingredients
|
C15 H24 O5
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_used_for
|
treatment of malaria
|
|
gptkbp:lifespan
|
1-2 hours
|
|
gptkbp:marketed_as
|
gptkb:artesunate
DHA-PP
|
|
gptkbp:metabolism
|
metabolized in the liver
|
|
gptkbp:pharmacokinetics
|
well absorbed
rapidly acting
|
|
gptkbp:price
|
affordable
|
|
gptkbp:provides_information_on
|
included in malaria treatment guidelines
|
|
gptkbp:research_areas
|
various universities
|
|
gptkbp:research_focus
|
combination therapies
new formulations
|
|
gptkbp:safety_features
|
generally safe
|
|
gptkbp:side_effect
|
gptkb:fandom
dizziness
headache
nausea
allergic reactions
liver enzyme elevation
|
|
gptkbp:social_structure
|
sesquiterpene lactone
|
|
gptkbp:targets
|
gptkb:Plasmodium_falciparum
gptkb:Plasmodium_vivax
|
|
gptkbp:treatment
|
gptkb:artemether-lumefantrine
gptkb:dihydroartemisinin-piperaquine
|
|
gptkbp:type_of
|
71939-50-9
|
|
gptkbp:water_resistance
|
low resistance development
|
|
gptkbp:year_created
|
1970s
|